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Integrated continuous biomanufacturing has gained significant interest because of its potential to streamline 
production by integrating upstream and downstream processes.  Combined with an intensified perfusion 
bioreactor, continuous processing can greatly reduce cost, space requirements, and handling steps, while 
improving production efficiency.1,2 During perfusion operation, product and spent media are removed while cells 
are retained within the bioreactor with a cell separation device. In particular hollow fiber membranes, attached 
externally to the bioreactor, permit tangential or alternating flow filtration (TFF, ATF), as cells are recirculated 
through the unit and permeate is harvested for downstream processing.3,4 However, membrane fouling and 
issues with product sieving, especially associated with a TFF setup, have a direct impact on total product yield 
from the process, and can cause hollow fiber reliability issues which in some cases can result in premature 
termination of a bioreactor run. It is hypothesized that membrane fouling from host cell proteins, cell debris, or 
additives such as antifoam can result in decreased product sieving as product transmission through the 
membrane decreases over time.5,6 Toward addressing issues with product sieving, we aim to identify the 
underlying causes of membrane fouling, associated with host cell proteins and antifoam, and to develop new 
methods to lengthen their lifetime during perfusion operation. This presentation will focus on some tools and 
experiments that we have conducted to address this issue with the goal to identify factors within the bioreactor 
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